Future Fund LLC Has $3.76 Million Holdings in Guardant Health, Inc. $GH

Future Fund LLC cut its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 10.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,827 shares of the company’s stock after selling 4,459 shares during the quarter. Guardant Health comprises about 1.3% of Future Fund LLC’s holdings, making the stock its 13th largest position. Future Fund LLC’s holdings in Guardant Health were worth $3,762,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of GH. Knights of Columbus Asset Advisors LLC bought a new position in Guardant Health during the third quarter worth $1,554,000. Erste Asset Management GmbH boosted its stake in Guardant Health by 10.4% during the third quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock worth $43,716,000 after acquiring an additional 66,617 shares in the last quarter. Segall Bryant & Hamill LLC boosted its stake in Guardant Health by 57.8% during the third quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock worth $19,066,000 after acquiring an additional 111,822 shares in the last quarter. TD Asset Management Inc boosted its stake in Guardant Health by 16.1% during the third quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock worth $11,797,000 after acquiring an additional 26,210 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its stake in Guardant Health by 155.5% during the third quarter. GSA Capital Partners LLP now owns 21,982 shares of the company’s stock worth $1,373,000 after acquiring an additional 13,378 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Trading Down 2.6%

Guardant Health stock opened at $129.69 on Friday. Guardant Health, Inc. has a 1-year low of $38.03 and a 1-year high of $133.97. The firm has a market capitalization of $17.20 billion, a price-to-earnings ratio of -38.26 and a beta of 1.48. The firm’s fifty day moving average price is $95.08 and its two-hundred day moving average price is $99.94.

Insider Transactions at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 210,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total value of $23,076,900.00. Following the transaction, the chief executive officer directly owned 1,886,504 shares of the company’s stock, valued at approximately $207,307,924.56. This trade represents a 10.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Terilyn J. Monroe sold 3,832 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $92.68, for a total transaction of $355,149.76. Following the completion of the transaction, the insider directly owned 20,990 shares in the company, valued at $1,945,353.20. This trade represents a 15.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 332,244 shares of company stock valued at $36,156,026. Corporate insiders own 5.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on GH shares. Wells Fargo & Company increased their target price on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. JPMorgan Chase & Co. increased their target price on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. BTIG Research set a $160.00 target price on shares of Guardant Health and gave the stock a “buy” rating in a research note on Wednesday. Canaccord Genuity Group increased their target price on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Finally, Barclays increased their target price on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and an average price target of $129.79.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.